用于儿童和青少年的人乳头瘤病毒疫苗
Human papillomavirus vaccine for children and adolescents.
作者信息
Salvadori Marina I
机构信息
Canadian Paediatric Society, Infectious Diseases and Immunization Committee, Ottawa, Ontario.
出版信息
Paediatr Child Health. 2018 Jul;23(4):262-265. doi: 10.1093/pch/pxx179. Epub 2018 Jun 12.
Abstract
Human papillomavirus (HPV) is known to cause genital warts, cervical cancer, penile cancer, anal cancer and oropharyngeal cancer. In North America, the lifetime cumulative incidence of HPV infection is estimated at more than 70% for all HPV types combined. A safe and effective vaccine against nine HPV types is available. HPV vaccine should be administered routinely to all girls and boys between the ages of 9 and 13 years of age. All youth who have not received the vaccine in a routine program should receive the vaccine in a 'catch-up' program. Physicians caring for children and youth should advocate for funding and implementation of universal HPV vaccine programs.
摘要
已知人乳头瘤病毒（HPV）可引发尖锐湿疣、宫颈癌、阴茎癌、肛门癌和口咽癌。在北美，所有类型HPV感染的终生累积发病率估计超过70%。目前有一种针对九种HPV类型的安全有效疫苗。HPV疫苗应常规接种给所有9至13岁的女孩和男孩。所有未在常规项目中接种疫苗的青少年都应在“补种”项目中接种该疫苗。照顾儿童和青少年的医生应倡导为普遍的HPV疫苗项目提供资金并予以实施。
相似文献
1
Human papillomavirus vaccine for children and adolescents.用于儿童和青少年的人乳头瘤病毒疫苗
Paediatr Child Health. 2018 Jul;23(4):262-265. doi: 10.1093/pch/pxx179. Epub 2018 Jun 12.
2
Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.在日本，九价 HPV 疫苗对女童和妇女进行常规和补种接种的公共卫生影响和成本效益：基于模型的研究。
BMC Infect Dis. 2021 Jan 6;21(1):11. doi: 10.1186/s12879-020-05632-0.
3
Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.四价人乳头瘤病毒（HPV）疫苗在男性中的功效、免疫原性和安全性：一项随机、安慰剂对照、3 期临床试验的开放标签、长期扩展的结果。
Lancet Infect Dis. 2022 Mar;22(3):413-425. doi: 10.1016/S1473-3099(21)00327-3. Epub 2021 Nov 12.
4
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.评估奥地利九价人乳头瘤病毒疫苗全民接种计划的成本效益情况。
BMC Infect Dis. 2016 Apr 16;16:153. doi: 10.1186/s12879-016-1483-5.
5
Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.评估在欧洲为男童和女童接种 HPV 相关疾病疫苗的临床获益。
BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10.
6
Spectrum of genital human papillomavirus infection in a female adolescent population.女性青少年人群中生殖器人乳头瘤病毒感染的谱系
Sex Transm Dis. 1995 Jul-Aug;22(4):236-43. doi: 10.1097/00007435-199507000-00007.
7
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).四价人乳头瘤病毒疫苗：免疫实践咨询委员会（ACIP）的建议
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
8
The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.匈牙利四价人乳头瘤病毒（6/11/16/18）疫苗的成本效益。
J Med Econ. 2010 Mar;13(1):110-8. doi: 10.3111/13696990903546013.
9
[HPV vaccination in boys and men : update and recommendations].[男孩和男性的人乳头瘤病毒疫苗接种：更新与建议]
Rev Med Brux. 2018;39(4):352-358.
10
Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.重点介绍四价人乳头瘤病毒（6、11、16、18 型）重组疫苗（佳达修®）在预防女性的癌前生殖器病变、生殖器癌和生殖器疣方面的作用。
BioDrugs. 2011 Oct 1;25(5):339-43. doi: 10.2165/11205060-000000000-00000.
引用本文的文献
1
Estimating the Age of Disease-causal HPV Infection Based on the Natural History of CIN2+ Among Females in Canada.基于加拿大女性中CIN2+的自然史估算致病型人乳头瘤病毒感染的年龄
Open Forum Infect Dis. 2025 Mar 17;12(4):ofaf168. doi: 10.1093/ofid/ofaf168. eCollection 2025 Apr.
2
Knowledge and attitudes about human papillomavirus infection and prevention methods among medical science students in Novi Sad, Serbia: a cross-sectional study.塞尔维亚诺维萨德医科学生对人乳头瘤病毒感染及预防方法的认知与态度：一项横断面研究
BMC Public Health. 2025 Jan 27;25(1):332. doi: 10.1186/s12889-025-21593-y.
3
Stakeholders' perspectives on barriers to and facilitators of school-based HPV vaccination in the context of COVID-19 pandemic-related disruption: a qualitative mixed methods study.利益相关者对 COVID-19 大流行相关干扰背景下基于学校的 HPV 疫苗接种障碍和促进因素的看法：一项定性混合方法研究。
Int J Qual Stud Health Well-being. 2024 Dec;19(1):2295879. doi: 10.1080/17482631.2023.2295879. Epub 2023 Dec 20.
4
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.ECTRIMS/EAN 关于多发性硬化症患者接种疫苗的共识：在高度活跃的免疫治疗药物时代改进免疫策略。
Mult Scler. 2023 Jul;29(8):904-925. doi: 10.1177/13524585231168043. Epub 2023 Jun 9.
5
Knowledge about HPV Infection and the HPV Vaccine among Parents in Southeastern Serbia.HPV 感染和 HPV 疫苗在塞尔维亚东南部父母中的认知。
Medicina (Kaunas). 2022 Nov 22;58(12):1697. doi: 10.3390/medicina58121697.
6
Human papillomavirus (HPV) vaccination across a cascade of knowledge, willingness, and uptake among gay, bisexual, and other men who have sex with men in Canada's three largest cities.在加拿大三个最大城市的男同性恋、双性恋和其他与男性发生性关系的男性中，人乳头瘤病毒（HPV）疫苗在知识、意愿和接种率方面呈级联式增长。
Hum Vaccin Immunother. 2021 Dec 2;17(12):5413-5425. doi: 10.1080/21645515.2021.1979379.
7
Newcomer knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination.HPV 疫苗接种相关的新知识、态度和信念。
BMC Fam Pract. 2021 Jan 9;22(1):17. doi: 10.1186/s12875-020-01360-1.
8
HPV Vaccine and College-Age Men: A Scoping Review.人乳头瘤病毒疫苗与大学年龄男性：范围综述。
Am J Mens Health. 2020 Nov-Dec;14(6):1557988320973826. doi: 10.1177/1557988320973826.
9
Assessment of School Anti-Bullying Interventions: A Meta-analysis of Randomized Clinical Trials.学校反欺凌干预措施的评估：随机临床试验的荟萃分析。
JAMA Pediatr. 2021 Jan 1;175(1):44-55. doi: 10.1001/jamapediatrics.2020.3541.
10
Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study.报告加拿大临床实践指南制定者的财务利益冲突：描述性研究。
CMAJ. 2020 Jun 8;192(23):E617-E625. doi: 10.1503/cmaj.191737.
本文引用的文献
1
Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) .人乳头瘤病毒（HPV）疫苗最新情况：一份咨询委员会声明（ACS） 国家免疫咨询委员会（NACI）
Can Commun Dis Rep. 2012 Jan 2;38(ACS-1):1-62. doi: 10.14745/ccdr.v38i00a01.
2
Tempest in a teapot: A systematic review of HPV vaccination and risk compensation research.小题大做：人乳头瘤病毒疫苗接种与风险代偿研究的系统评价
Hum Vaccin Immunother. 2016 Jun 2;12(6):1435-50. doi: 10.1080/21645515.2016.1141158. Epub 2016 Feb 10.
3
Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults.四价人乳头瘤病毒疫苗在 HIV 感染和 HIV 阴性青少年和年轻成人中的安全性和免疫原性。
Vaccine. 2014 Sep 29;32(43):5657-61. doi: 10.1016/j.vaccine.2014.08.011. Epub 2014 Aug 20.
4
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.两剂 HPV 疫苗在青少年中的免疫原性与三剂 HPV 疫苗在年轻女性中的免疫原性比较：一项随机临床试验。
JAMA. 2013 May 1;309(17):1793-802. doi: 10.1001/jama.2013.1625.
5
Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose.接受首剂四价疫苗的年轻女性中人乳头瘤病毒感染的患病率。
Arch Pediatr Adolesc Med. 2012 Aug;166(8):774-6. doi: 10.1001/archpediatrics.2012.586.
6
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.HPV 疫苗预防肛门 HPV 感染和肛门上皮内瘤变。
N Engl J Med. 2011 Oct 27;365(17):1576-85. doi: 10.1056/NEJMoa1010971.
7
Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.四价人乳头瘤病毒疫苗接种与澳大利亚生殖器疣的趋势：全国哨点监测数据分析。
Lancet Infect Dis. 2011 Jan;11(1):39-44. doi: 10.1016/S1473-3099(10)70225-5. Epub 2010 Nov 8.
8
Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.人乳头瘤病毒（HPV）疫苗的安全性：迄今为止的国际经验综述。
Vaccine. 2009 Dec 9;27(52):7270-81. doi: 10.1016/j.vaccine.2009.09.097. Epub 2009 Sep 30.
9
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.四价人乳头瘤病毒重组疫苗上市后安全性监测
JAMA. 2009 Aug 19;302(7):750-7. doi: 10.1001/jama.2009.1201.
10
Human papillomavirus vaccine for children and adolescents.用于儿童和青少年的人乳头瘤病毒疫苗
Paediatr Child Health. 2007 Sep;12(7):599-610.
Zotero 插件